5747-48-8

Basic information

• Product Name: N-Des[2-(2-hydroxyethoxy)ethyl] Quetiapine
• Synonyms: 11-(piperazin-1-yl)dibenzo[b,f][1,4]thiazepine;11-Piperazinodibenzo[b,f][1,4]thiazepine;N-Desalkylquetiapine;Norquetiapine;2-(Piperazin-1-yl)dithiazepin;11-(Piperazin-1-yl);11-(1-Piperazinyl)-dibenzo[b,f][1,4]thiazepine;N-Des[2-(2-hydroxyethoxy)ethyl] Quetiapine
• CAS NO: 5747-48-8
• Molecular Formula: C₁₇H₁₇N₃S
• Molecular Weight: 295.41
• Product Categories: Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 5747-48-8.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 465.2 °C at 760 mmHg
• Flash Point: 235.2 °C
• Appearance: Pale-Yellow Solid
• Density: 1.30
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 8.55±0.10(Predicted)
• CAS DataBase Reference: N-Des[2-(2-hydroxyethoxy)ethyl] Quetiapine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Des[2-(2-hydroxyethoxy)ethyl] Quetiapine(5747-48-8)
• EPA Substance Registry System: N-Des[2-(2-hydroxyethoxy)ethyl] Quetiapine(5747-48-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 5747-48-8(Hazardous Substances Data)

Usage

Description

N-Des[2-(2-hydroxyethoxy)ethyl] Quetiapine is a derivative of Quetiapine, a Benzothiazepine with mixed serotonin and dopamine receptor antagonistic properties. It is a metabolite of Quetiapine and is characterized by its pale-yellow solid appearance. N-Des[2-(2-hydroxyethoxy)ethyl] Quetiapine is utilized in various applications due to its unique chemical properties and pharmacological effects.

Uses

Used in Pharmaceutical Industry:
N-Des[2-(2-hydroxyethoxy)ethyl] Quetiapine is used as an antipsychotic agent for the treatment of various psychiatric disorders. Its application is based on its ability to modulate serotonin and dopamine receptor activity, which contributes to its effectiveness in managing symptoms associated with schizophrenia, bipolar disorder, and other related conditions.
Used in Research and Development:
In the field of pharmaceutical research and development, N-Des[2-(2-hydroxyethoxy)ethyl] Quetiapine serves as a valuable compound for studying the mechanisms of action and potential therapeutic applications of mixed serotonin and dopamine receptor antagonists. This knowledge can be applied to the development of new drugs with improved efficacy and reduced side effects.
Used in Drug Delivery Systems:
Similar to Gallotannin, N-Des[2-(2-hydroxyethoxy)ethyl] Quetiapine can be incorporated into novel drug delivery systems to enhance its bioavailability, delivery, and therapeutic outcomes. These systems may include organic and metallic nanoparticles, which can improve the compound's solubility, stability, and targeted release, ultimately leading to better treatment outcomes for patients.

Upstream product

• 111974-69-7 Quetiapine 
• 13745-86-3 11-chloro-dibenzo[b,f][1,4]thiazepine 
• 3159-07-7 dibenzo[b,f][1,4]thiazepin-11-one 
• 111974-73-3 phenyl [2-(phenylsulphanyl)phenyl]carbamate 
• 1134-94-7 2-phenylsulfanyl-aniline 
• 4171-83-9 2-nitrophenyl phenyl sulfide 
• 88-73-3 2-Chloronitrobenzene 
• 108-98-5 thiophenol 
• 1217310-64-9 (E)-tert-butyl 4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazine-1-carboxylate 
• 110-85-0 piperazine 
• 1176987-11-3 C₁₃H₁₀N₂S*ClH 
• 111974-74-4 N-Dealkyl Quetiapine dihydrochloride 
• 546-68-9 titanium(IV) isopropylate 
• 753475-15-9 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine hydrochloride 

Downstream Products

• 111974-74-4 N-Dealkyl Quetiapine dihydrochloride 
• 753475-15-9 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine hydrochloride 
• 111974-69-7 Quetiapine 
• 1031703-38-4 2-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethanol-1,1,2,2-D₄ 

Relevant articles and documents

Butyl methacrylate-co-ethylene glycol dimethacrylate monolith for online in-tube SPME-UHPLC-MS/MS to determine chlopromazine, clozapine, quetiapine, olanzapine, and their metabolites in plasma samples

This manuscript describes a sensitive, selective, and online in-tube solid-phase microextraction coupled with an ultrahigh performance liquid chromatography-tandem mass spectrometry (in-tube SPME-UHPLC-MS/MS) method to determine chlopromazine, clozapine, quetiapine, olanzapine, and their metabolites in plasma samples from schizophrenic patients. Organic poly(butyl methacrylate-co-ethylene glycol dimethacrylate) monolith was synthesized on the internal surface of a fused silica capillary (covalent bonds) for in-tube SPME. Analyte extraction and analysis was conducted by connecting the monolithic capillary to an UHPLC-MS/MS system. The monolith was characterized by scanning electron microscopy (SEM) and Fourier transform infrared spectrometry (FTIR). The developed method presented adequate linearity for all the target antipsychotics: R2 was higher than 0.9975, lack-of-fit ranged from 0.115 to 0.955, precision had variation coefficients lower than 14.2%, and accuracy had relative standard error values ranging from ?13.5% to 14.6%, with the exception of the lower limit of quantification (LLOQ). The LLOQ values in plasma samples were 10 ng mL?1 for all analytes. The developed method was successfully applied to determine antipsychotics and their metabolites in plasma samples from schizophrenic patients.

Design, synthesis and anticancer activity of N-(1-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl derivatives

Novel N-(1-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl derivatives were designed, synthesized and their chemical structures were confirmed by 1H NMR, 13C NMR and Mass spectra. The anticancer activities of the newly synthesized compounds were evaluated in vitro against three human cancer cell lines including K562, Colo-205 and MDA-MB 231 by MTT assay. The screening results showed that five compounds (16b, 16d, 16i, 16p and 16q) exhibited potent cytotoxic activities with IC50 values between 20 and 40 μM. Further in vitro studies revealed that inhibition of sirtuins could be the possible mechanism of action of these molecules.

DIBENZOTHIAZEPINE MODULATORS OF DOPAMINE, ALPHA ADRENERGIC, AND SEROTONIN RECEPTORS

The present invention relates to new dibenzothiazepine modulators of D1 receptors, D2 receptors, alpha-1 adrenergic receptors, alpha-2 adrenergic receptors, H1 receptors, 5-HT1A receptors, and/or 5-HT2 receptors, pharmaceutical compositions thereof, and methods of use thereof.